Byetta is not semaglutide: GLP-1 history needs a fact-check

What did @nursebaeblair actually say?

The transcript for this video is, bluntly, not usable for fact-checking. The audio captured by the transcription tool is the lyrics to No Doubt's "Just a Girl," not the creator's commentary on diabetes or GLP-1 medications. The caption, however, does make specific claims worth examining: that the creator has had type 2 diabetes since age 11, that her case was "highly atypical" because she was not significantly overweight, and that Byetta was "one of the first forms of semiglutide" available more than 20 years ago. That last claim is medically incorrect, and it matters enough to address directly.

Does the science back this up?

On the atypical presentation point, yes, largely. Lean or non-obese type 2 diabetes is a real and underappreciated phenotype. A 2020 study by Lim et al. in Diabetes Care documented that roughly 10-20% of people with type 2 diabetes globally are classified as normal weight at diagnosis, with higher rates in Asian populations. Childhood-onset type 2 in a non-obese patient is unusual but documented, and these patients often have stronger genetic contributions to insulin resistance or secretion defects. So the "atypical" framing is clinically reasonable. On Byetta being a form of semaglutide, the science does not back this up at all.

What did they get wrong (or right)?

Let's be direct: Byetta (exenatide) is not semaglutide, not a precursor to semaglutide, and not "one of the first forms" of semaglutide. They are both GLP-1 receptor agonists, meaning they work on the same receptor, but they are entirely different molecules. Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the saliva of the Gila monster lizard. Semaglutide, developed by Novo Nordisk, is a human GLP-1 analogue with fatty acid modifications that extend its half-life. Byetta was FDA-approved in 2005. Semaglutide came later, with Ozempic approved in 2017. Calling Byetta an early form of semaglutide is like calling atenolol an early form of metoprolol because both are beta-blockers. The drug class is shared; the molecule is not. The caption also misspells semaglutide as "semiglutide," which is a minor but telling slip for someone framing themselves as a medical authority.

What should you actually know?

GLP-1 receptor agonists are a drug class, not a single drug. Understanding the difference matters, especially as compounded versions of semaglutide and tirzepatide circulate online. Exenatide (Byetta, Bydureon) was genuinely an early and important drug in this class, and participation in Byetta trials as a child would be a legitimate and interesting medical history. That story deserves accurate framing. The creator's personal experience with lean type 2 diabetes from childhood is clinically relevant and worth sharing. But conflating drug classes with specific molecules spreads confusion at a moment when patients are already overwhelmed trying to sort out Ozempic from Wegovy from compounded semaglutide from tirzepatide. If you are managing type 2 diabetes or considering a GLP-1 medication, the drug name and molecular identity matter for efficacy, dosing, and safety profiles. A telehealth provider or endocrinologist can help you understand which agent, if any, is appropriate for your situation.